MYGN

4:02 pm Myriad Genetics and Institut Pasteur publish initial results from study of immunoe response: ‘results could lead to the development of novel diagnostics and companion diagnostics’

moreView todays social media effects on MYGNView the latest stocks trending across Twitter. Click to view dashboardSee who Myriad is hiring next, click here to view […]

March 21, 2014 Bystocknews MYGN, stock Comments Off read more

7:08 am Myriad Genetics notes that the National Comprehensive Cancer Network has revised its medical guidelines to expand Lynch syndrome screening

moreView todays social media effects on MYGNView the latest stocks trending across Twitter. Click to view dashboardSee who Myriad is hiring next, click here to view […]

March 5, 2014 Bystocknews MYGN, stock Comments Off read more

Myriad Publishes Clinical Utility Study for Prolaris(R)

[at noodls] – SALT LAKE CITY, March 3, 2014 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it has published data from the PROCEDE 500 study in the journal Current Medical Research and Opinion, … moreView todays social media effects on MYGNView the latest stocks trending across Twitter. Click to view dashboardSee who Myriad is hiring next, click […]

March 3, 2014 Bystocknews MYGN, stock Comments Off read more

7:11 am Myriad Genetics publishes data from the PROCEDE 500 study in the journal Current Medical Research and Opinion, demonstrating that 65% of physicians changed their original treatment plans for men with prostate cancer based on results

moreView todays social media effects on MYGNView the latest stocks trending across Twitter. Click to view dashboardSee who Myriad is hiring next, click here to view […]

March 3, 2014 Bystocknews MYGN, stock Comments Off read more

4:02 pm Myriad Genetics and Institut Pasteur publish initial results from study of immunoe response: ‘results could lead to the development of novel diagnostics and companion diagnostics’

7:08 am Myriad Genetics notes that the National Comprehensive Cancer Network has revised its medical guidelines to expand Lynch syndrome screening

Myriad Publishes Clinical Utility Study for Prolaris(R)

7:11 am Myriad Genetics publishes data from the PROCEDE 500 study in the journal Current Medical Research and Opinion, demonstrating that 65% of physicians changed their original treatment plans for men with prostate cancer based on results

MYRIAD GENETICS INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Financial Statements and

Medical Research Providers Ride Higher With Biotechs

Myriad Genetics rises after court grants U. of Utah motion related to BRCA tests

Myriad Genetics Unveils Prolaris Data

The 5 Most Hated Biotechs: Myraid, Sarepta, Questcor, Ziopharm, and MannKind

Why Myriad Genetics Inc. Shares Jumped